The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...
Genentech Data at ESMO 2025 Showcase Advances in Science and Cancer Care Across Multiple Tumor Types
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that it will present more than 30 abstracts across more than 10 ...
Phase II Study of Vismodegib in Patients With SMO- or PTCH1-Mutated Tumors: Results From the National Cancer Institute Molecular Analysis for Therapy Choice Eastern Cooperative Oncology Group-American ...
Orionis Biosciences, a privately held company, announced a second multi-year collaboration with Genentech, a member of the Roche Group (OTCQX:RHHBY) on Wednesday. The goal of this partnership is to ...
– The Itovebi (inavolisib)-based regimen reduced the risk of death by more than 30% in people with PIK3CA-mutated HR-positive, HER2-negative advanced breast cancer, compared with palbociclib and ...
In 2020, immuno-oncology was at an inflection point. The first wave of PD1 blockers had shown that immune checkpoint inhibitors could be transformative for some cancer patients. But next-generation ...
Boston-based PatientsLikeMe, a hub for crowd-sourced patient data and an open research platform, has announced its most wide-reaching pharma partnership yet, a five-year agreement to share data with ...
Senior leadership roles at Guardant Health, Genentech and PfizerRegulatory, clinical and commercial expertise in therapeutics and biomarkersWill assist with osteosarcoma regulatory advice and oncology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results